Drugs for Lung Cancer Flashcards

(38 cards)

1
Q

TKI’s

A

The “nibs”
Blocks the EGFR pathway which, upon binding of a ligand, dimerizes and through series of pathways, is transducer to the nucleus where effects upon nuclear transcription can lead to cell growth and proliferation.
**Often a gain of function mutation in many cancers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is downstream from EFGR?

A

Kras, Braf, Mek, Erk/MAPK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does fusion of EML4/ERK do?

A

Produces activation of the MEK/ERK pathway and cell proliferation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Are mutations only found in patients who have a history of smoking?

A

NO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What type of cancer is genetic testing important for?

A

Adenocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What mutations are required to be tested for?

A

KRAS, EFGR, ALK rearrangement.

Other mutations such as BRAF, MET, etc can also be appropriate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do you test for EFGR?

A

DNA sequencing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How do you test for ALK fusion gene?

A

FISH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Who are ALK mutations more common in?

A

Non Smokers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Who are EFGR and mutations more common in?

A

Non Smokers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What does the US Preventive Services Task Force recommend?

A

Smokers between 55-80 yrs old with >30yr pack history and those who have quit within the past 15yrs should get low dose CTs of their lungs to look for possible tumors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Treatment of SCLC

A

Metastasis occurs early so chemotherapy/radiation is the only option.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treatment of NSCLC

A

In early stages, surgical resection if there has been no metastasis.
Tx used in adjuvant, neoadjuvant, or maintenance role to reduce the bulk of the tumor prior to resection, to eradicate micro metastases, and to prevent growth and metastasis.
Pre operative chemo may, however, delay potentially curative surgery.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Metastasis of NSCLC

A

Usually very early and most commonly to the adrenals, liver, brain and bone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Standard Chemotherapy for SCLC

A

Etoposide + Cisplatin or Carboplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Standard Treatment for NSCLC

A

Cisplatin AND Paclitaxel, Gemcitabine, Docetaxel, Vinorelbine, Irinotecan, or Pemetrexed

+EFGR TKIs for patients with EFGR positive testing.
+Bevacizumab for patients with non squamous histology, no brain metastasis, no hemptysis.

17
Q

Pemetrexed

A

Methotrexate analog (DHFR inhibitor). Maintainance dosing given for patients with stable or responding disease following 4 cycles of nonpemetrexed-platinium combination therapy.

18
Q

MOA of Carboplatin, Cisplatin

A

Forms DNA inter strand cross links and adducts

19
Q

MOA of Cyclophosphamide

A

Pro-drug of active alkylating moiety

20
Q

MOA if Docetaxel

A

Microtubule stabilizer inhibiting depolymerization

21
Q

MOA of Doxorubicin.

A

Intercalator, free radical generator, topo II inhibitor

22
Q

MOA of Etoposide, VP-16

A

DNA-topo II complex stabilizer

23
Q

MOA of Gemcitabine

A

DNA polymerase inhibitorvia incorporation of triphosphate form during DNA synthesis

24
Q

MOA of Ifosfamide

A

Intra and Inter strand crosslinker

25
MOA of Irinotecan
DNA-topo I complex stabilizer
26
MOA of Paclitaxel
Microtubule stabilizer inhibiting depolymerization
27
MOA of Pemetrexed
DHFR inhibitor
28
MOA of Topotecan
DNA topo I complex stabilizer
29
MOA of Vincristine, Vinorelbine
Microtubule inhibitor; Tubules disintegrate into spiral aggregates/ protofilaments
30
Cisplatin Toxicities
Nephrotoxicty, Ototoxicity.
31
Cyclophosphamide Toxicities
Hemorrhagic Cystitis
32
Docetaxel Toxicities
Sensory Neuropathy
33
Doxirubicin Toxicities
Cardiotoxicity in cummulative dose exposure.
34
Etoposide Toxicities
Alopecia
35
Vinca Alkaloid Toxicity
Neuropathic Toxicities
36
Erlotinib
``` Reversible inhibitor of EFGR Oral administration. CYP Substrate. Smoking increases clearance. Interstitial lung type events can occur. Liver, Kidney problems. Stomach or intestinal perforation. Corneal perforation/ulceration. Rash ```
37
Afatinib
Covalent inhibitor of EFGR, HER2, HER4. Oral administration. Similar problems of bioavailability and rash like Erlotinib but less overall side effects. **Rare pulmonary toxicity in Asian ethnicity.
38
What is a common side effect of EGFR/ TKI
Rash is common and is often used as proof for physicians that the drug has reached effective concentration levels.